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Abstract
Background: With the lengthening of life expectancy among HIV-positive subjects related to the use of highly active
antiretroviral treatments, an increased risk of cancer has been described in industrialized countries. The question is to
determine what occurs now and will happen in the future in the low income countries and particularly in sub-Saharan Africa
where more than two-thirds of all HIV-positive people live in the world. The objective of our paper is to review the link
between HIV and cancer in sub-Saharan Africa, putting it in perspective with what is already known in Western countries.
Methods and Findings: Studies for this review were identified from several bibliographical databases including Pubmed,
Scopus, Cochrane, Pascal, Web of Science and using keywords ‘‘HIV, neoplasia, epidemiology and Africa’’ and related MesH
terms. A clear association was found between HIV infection and AIDS-classifying cancers. In case-referent studies, odds
ratios (OR) were ranging from 21.9 (95% Confidence Interval (CI) 12.5–38.6) to 47.1 (31.9–69.8) for Kaposi sarcoma and from
5.0 (2.7–9.5) to 12.6 (2.2–54.4) for non Hodgkin lymphoma. The association was less strong for invasive cervical cancer with
ORs ranging from 1.1 (0.7–1.2) to 1.6 (1.1–2.3), whereas ORs for squamous intraepithelial lesions were higher, from 4.4 (2.3–
8.4) to 17.0 (2.2–134.1). For non AIDS-classifying cancers, squamous cell conjunctival carcinoma of the eye was associated
with HIV in many case-referent studies with ORs from 2.6 (1.4–4.9) to 13.0 (4.5–39.4). A record-linkage study conducted in
Uganda showed an association between Hodgkin lymphoma and HIV infection with a standardized incidence ratio of 5.7
(1.2–17) although OR in case-referent studies ranged from 1.4 (0.7–2.8) to 1.6 (1.0–2.7). Other cancer sites found positively
associated with HIV include lung, liver, anus, penis, vulva, kidney, thyroid and uterus and a decreased risk of female breast
cancer. These results so far based on a relatively small number of studies warrant further epidemiological investigations,
taking into account other known risk factors for these tumors.
Conclusion: Studies conducted in sub-Saharan Africa show that HIV infection is not only strongly associated with AIDS-
classifying cancers but also provided some evidence of association for other neoplasia. African countries need now to
implement well designed population-based studies in order to better describe the spectrum of AIDS-associated
malignancies and the most effective strategies for their prevention, screening and treatment.
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Introduction
Infection with the human immunodeficiency virus (HIV) entails
an increased risk of developing cancer [1]. Cancers such as Kaposi
Sarcoma (KS), Non Hodgkin Lymphoma (NHL) and Invasive
Cancer of the Cervix (ICC) have been recognized for a long time
as associated with HIV infection and have been classified as AIDS-
defining diseases. More recently, and concomitantly with the
lengthening of life expectancy related to the use of Highly Active
Antiretroviral Therapy (HAART), an increased risk of other
cancers has been found among HIV-positive subjects; they are
classified among the non-AIDS defining diseases. This association
was originally described in Western countries, where cancer
currently accounts for approximately one-third of the causes of
death in the patients infected with HIV [2]. The question is now to
determine what happens in the low incomes countries and
particularly sub-Saharan Africa where more than two-thirds of
all HIV-positive people live and where the HAART roll-out is now
well under way [3].
The objective of our paper is to review the evidence on the link
between HIV and cancer in sub-Saharan Africa, putting it in
perspective with what is already known in Western countries. A
better understanding of the link between HIV and cancer is indeed
necessary for the improvement of care of HIV-infected subjects as
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8621well as may shed understanding on the mechanisms of cancer
occurrence in the general population.
Methods
Studies from Africa were identified from several bibliographical
databases (Medline, Scopus, Cochrane library, Web of Science, Francis and
Pascal), using keywords ‘‘HIV’’ (including MesH term ‘‘HIV
infections’’), ‘‘neoplasia’’ (including MesH term ‘‘neoplasms’’) and
‘‘Africa’’ (621 references). We then selected all case-referent and
observational cohort studies as well as reviews published between
1992 and April 2008 (139 references). For AIDS-defining and non
AIDS-defining cancer trends in sub-Saharan Africa, we included
data from population-based cancer registries and of course
preferably selected studies linking these registries with AIDS
registries.
Similarly, references from Western countries were identified
from Pubmed using keywords ‘‘HIV’’ (including MesH term ‘‘HIV
infections’’), ‘‘neoplasia’’ (including MesH term ‘‘neoplasms’’) and
‘‘epidemiology’’ (2448 references). In order to have an overview, as a
point of comparison, of what is currently known about the
epidemiological association between cancer and HIV in industri-
alized countries we focused this part of the review on references
published since 2000 essentially from studies that linked data from
population-based cancer registries and AIDS registries from
Europe and North America and Australia (92 references).
International Agency for Research on Cancer (IARC) mono-
graphs were also included.
Measures of association between HIV and cancer varied in the
published materials, depending on study design. All measures, be
they Standardized Incidence Ratio (SIR) or Hazard Ratio (HR) in
cohort studies or Odds Ratios (OR) in case-referent studies can be
taken as estimates of relative risk (RR) and express by how much
the risk of cancer is increased in HIV-positive versus HIV negative
subjects. We report the original measures and their confidence
intervals (CI) as they were published.
Results
AIDS-defining cancers
Kaposi sarcoma. Since the first report by Hymes et al,o f
atypical occurrence of KS among homosexual men in 1981 [4],
KS has become the most frequent neoplasm in AIDS patients.
Before the HIV epidemic, this mesenchymal tumor involving
blood and lymphatic vessels was very infrequent in Western
countries with an incidence rate of 0.1 case per one million person-
years (py) in Northern Europe and United States of America
(USA). Higher rates were observed in countries around the
Mediterranean sea [5] where its classical form [6], occurring
mostly in elderly men, was originally described. With the HIV
epidemic, KS incidence quickly increased in Western countries
involving young, more often homosexual or bisexual than
heterosexual men or drug addicts. KS-associated herpes virus,
also known as Human Herpes Virus 8 (HHV8) is recognized as the
necessary cofactor in the pathogenesis of KS, irrespective of the
epidemiological setting [7,8]. Many studies showed that HAART
reduced the KS incidence in Western countries. The cohort study
‘‘EuroSIDA’’ reported a decrease in the incidence rate from 24.7
cases (95% CI 17.2–32.2) per 1000 py in 1994 to 4.7 (95% CI 2.7–
6.7) per 1000 py in 1997 and 1.7 (95% CI 0.7–3.4) per 1000 py in
recent years among HIV-infected individuals [9].
Sub-Saharan Africa. In sub-Saharan Africa, KS has been
much more frequent than in Western countries even before the
HIV epidemic, and the African-endemic form has been described
since the 1960s. [10]. A role of environmental factors was
suggested based on geographical variations [11]. With the AIDS
epidemic, the atypical epidemic form of KS has become more
frequent in several parts of Africa [12,13]. It has a commonly
aggressive presentation with unusual localisations and frequent
visceral organs’ involvement. The median survival for childhood
AIDS-related KS patients is less than two years [14]. The age at
diagnosis is younger than in the general population, affecting now
both men and women with two specific peaks: the first in
childhood (4–10 years of age) and the second in young adulthood
(30–40 years) [15]. The incidence of KS has been steadily climbing
in parallel with the AIDS epidemic in sub-Saharan Africa with a
20-fold increase in Uganda and Zimbabwe during the last 15 years
making KS the most common malignancy in men and the second
most common in women following ICC in these regions
[12,16,17]. Case referent studies conducted in South Africa and
in Rwanda found a clear association between HIV infection and
KS with ORs ranging from 21.9 (95% CI 12.5–38.6) to 47.1 (95%
CI 31.9–69.8) [18,19,20] (Figure 1) whereas a record linkage study
in Uganda only found a SIR around 5 to 6 [21]. KS was the
second most frequent cancer in children following Burkitt
lymphoma in a study conducted in Malawi in 2003 among
children (0–15 years) hospitalized for cancer. Among the 707
children enrolled, 61 (9%) had a KS of which 52 were infected by
HIV [22]. Newton et al found in a case-referent study carried out
in Kampala (Uganda) a particularly high risk of KS among HIV-
infected compared to HIV-negative children with an OR of 94.9
(95% CI 28.5–315.3) [23] (Figure 1).
Non-Hodgkin lymphoma. NHL is the second most
common malignant disorder associated with HIV infection
worldwide. After the first description in 1982 [24], a study of 90
homosexual men in whom a NHL established the link between
AIDS and NHL [25]. High-grade NHL was classified as AIDS-
defining in 1985 [26] and large B cell lymphomas were added in
1987 [27]. Studies conducted in Western countries showed that
the risk of NHL occurrence among HIV-infected subjects was
particularly high compared to HIV-negative subjects with relative
risks (RR) of at least 100 [28,29,30]. In the context of HIV
infection, the classic forms of NHL display a B-phenotype and
include Burkitt lymphoma, diffuse large B-cell lymphoma (nodal
or primary brain), primary effusion lymphoma and plasmablastic
lymphoma of the oral cavity [31]. There is a significant
relationship between the subtype of lymphoma and the HIV
disease status, with diffuse large B-cell lymphoma occurring in the
setting of profound immunodepression (CD4,100.10
6/L) and
Burkitt lymphoma in less immunodeficient patients.
In Western countries, the introduction of HAART induced a
significant reduction of the NHL incidence, although less marked
than for KS incidence. A first international meta-analysis based on
23 prospective studies compared the incidence of NHL between
1992–96 and 1997–99 [32]. This study confirmed a reduction in
the incidence of primary cerebral lymphoma (rate ratio=0.42
(99% CI 0.24–0.75)) and immunoblastic lymphoma (rate
ratio=0.57 (99% CI 0.39–0.85)). The incidence of Burkitt
lymphoma was not reduced (rate ratio=1.18 (99% CI 0.48–
2.88)) [32]. A recent study based on the Swiss HIV Cohort Study
evaluated the long-term effect of HAART on NHL incidence. The
authors found that the incidence of NHL in 1993–1995 i.e. before
HAART introduction was 13.6 cases per 1000 py and declined to
1.8 per 1000 py in 2002–2006. Thus, the use of HAART was
associated with a lower risk of NHL among HIV-infected people
(HR 0.26 (95% CI 0.20–0.33)) [33]. Moreover, the CD4 cell count
was inversely associated with NHL (HR 12.26 (95%CI 8.31–
18.07)) in the non-HAART users group whereas only age was
HIV and Cancer in Africa
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protection HAART confers persists regardless of the HAART
regimen [34]. Therefore, the cellular immunosuppression appears
to be the main risk factor for NHL, a situation shared by HIV-
infected people and transplant recipients [35].
Sub-Saharan Africa. Several NHL studies have been
conducted in sub-Saharan Africa. Data coming from a cancer
registry in Uganda showed an overall increase of the NHL annual
incidence in the nineties. In Kampala, Uganda, the NHL annual
incidence of just more than 3 cases per 100 000 py, stable up to
the early nineties, increased to 7.4 per 100 000 py during the
1995–1997 period [16]. Another study examined the frequency
and types of AIDS and non-AIDS related malignant lymphoma in
Tanzania. This study suggested a general overall trend of
increased frequency of malignant lymphoma from the late ‘80s
to the mid ‘90s [36]. Several case-referent studies undertaken in
South Africa, Uganda and Rwanda from the ‘90’s to the early
2000’s found a significant association between NHL and HIV
infection with ORs ranging from 5.0 (95% CI 2.7–9.5) to 12.6
(95% CI 2.2–54.4) [18,19,20,23] (Figure 2). A study conducted in
Uganda by Mbulaiteye et al showed a higher incidence of NHL
among HIV-infected people with a Standardized Incidence Ratio
(SIR) of 6.7 (95% CI 1.8–17) [21].
In children, malignant lymphoma is mostly represented by
endemic Burkitt lymphoma associated with early and persistent
Epstein-Barr Virus (EBV) infection. A case-referent study
conducted in Uganda by Parkin et al involved 132 children with
confirmed histological confirmed NHL. Most childhood lympho-
ma (90%) were EBV-positive Burkitt lymphoma, but no
association was found with HIV [37]. In Malawi, another survey
conducted in children showed an increase of NHL incidence over
time with only one case diagnosed in 1998 versus 10 cases in 2002
among the 30 cases of NHL registered during the 6 years of the
study. Among the 30 cases, eight (26.7%) had a positive HIV
serology. HIV-infected children had a slightly different clinical
presentation with lymphadenopathies predominantly located in
the head and neck area whereas HIV-negative children had
mainly intra-abdominal lymphadenopathies [22].
Cervical cancer. According to the World Health
Organization (WHO), ICC is the second most common cancer
in women worldwide, and is more frequent in low income
countries [38]. Annual global estimates around the year 2000 are
of approximately 500 000 new cases of, and 230 000 deaths from
cervical cancer. Eighty percent of these cases occur in the less
industrialized countries [39]. The association between human
papilloma virus (HPV), especially 16 and 18 types and ICC is now
well established [40]. Women infected with HIV have an
increased risk of also being HPV-infected and consequently are
at higher risk for cervical cancer [41,42]. ICC was classified as
AIDS-defining in 1993 [43]. In Western countries, women
infected with HIV are at a significantly increased risk for in situ
and ICCs. A study looking specifically at HPV-associated cancers
found for in situ cervical cancer an OR of 4.6 (4.3–5.0) and for
invasive an OR of 5.4 (3.9–7.2) [44]. In HIV-negative women,
Cervical Intraepithelial Neoplasia (CIN) can regress spontaneously
under the influence of the host’s immune system. However, a small
percentage of cases progress to become ICC. The mechanism by
which HIV increases the risk associated with HPV infection may
be linked to the immunodeficiency induced by HIV with a poor
control of HPV infection [45]. The incidence of this cancer does
not seem to have been substantially modified by the introduction
of HAART [46,47,48].
Sub-Saharan Africa. Cervical cancer is much more frequent
in sub-Saharan Africa, where it has been highly prevalent even
before the HIV epidemic, than in Western countries. Data coming
from different cancer registries showed contradictory trends. While
the Ugandan tumour registry finds increased cervical cancer rates
on the parallel rise of the HIV epidemic [16], the Zimbabwean
tumour registry did not identify any increase in the ICC incidence
during that same period [49]. Another study conducted in Kenya
Figure 1. Odds Ratio (OR) and corresponding 95% confidence interval (95% CI) for the association between Kaposi sarcoma and
HIV in sub-Saharan Africa.
doi:10.1371/journal.pone.0008621.g001
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highlighted that the three-fold increase in HIV prevalence during
this period was not followed by a similar trend concerning ICC
[50]. In sub-Saharan Africa, the association between HIV
infection and the ICC has been less much strong than the one
with KS and NHL. By contrast, several studies conducted in sub-
Saharan Africa indicate that among African women, being HIV-
infected was associated with a high risk of presenting squamous
intraepithelial lesions of the cervix, with ORs ranging from 4.4
(95% CI 2.3–8.4) to 17.0 (95% CI 2.2–134.1) depending on the
grade of the lesion and other factors [51,52,53,54] (Figure 3).Yet,
many case-referent studies conducted in Uganda [23,55], Rwanda
Figure 2. Odds Ratio (OR) and corresponding 95% confidence interval (95% CI) for the association between Non Hodgkin
lymphoma and HIV in sub-Saharan Africa.
doi:10.1371/journal.pone.0008621.g002
Figure 3. Odds Ratio (OR) and corresponding 95% confidence interval (95% CI) for the association between cervical abnormalities,
invasive cervical cancer and HIV in sub-Saharan Africa. * squamous intraepithelial lesions { low-grade SIL { high-grade SIL.
doi:10.1371/journal.pone.0008621.g003
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association between HIV and ICC, with ORs ranging from 1.1
(95% CI 0.7–1.2) to 1.6 (95% CI 0.7–3.6) (Figure 3).
However, findings from Mbulateye et al showed a higher
incidence of ICC among HIV-infected patients compared to the
general Ugandan population with a SIR of 2.4 (95% CI 1.1–4.4)
[21]. Case-referent studies in South Africa also found a significant
association with ORs of 1.6 (95% CI 1.1–2.3) and 1.6 (95% CI
1.3–2.0) [18,20]. An association between HPV and HIV infection
has been documented in several studies. According to a recent
case-referent study conducted in South Africa, HIV-positive
women were nearly five times more likely to have high-risk
HPV-infection compared to HIV-negative women (OR 4.6 (95%
CI 2.8–7.5))[52]. In another case-referent study conducted in
Kenya, HIV-positive women were also more likely to be HPV-
infected compared to HIV-negative women (OR 3.1 (95% CI 1.6–
5.9)) [57]. In West Africa, a particular attention was given to the
association between HIV and cervical abnormalities according to
the HIV-1 or HIV-2 status. HIV-1 is the most widespread type
worldwide. HIV-2 is less frequent and is essentially found in West
Africa where its prevalence represent less than 5% of HIV
infection. A study conducted in Senegal found an association
between the HIV and HPV infections for the two types of HIV:
HIV-1 (OR 2.9 (95% CI 1.7–4.9)) and HIV-2 (OR 1.7 (95% CI
1.0–2.9)) [58]. Concurrently, Hawes et al found that, among
women infected with high-risk HPVs, HIV-2 infected Senegalese
women were at a higher risk to have a high-grade CIN or ICC
(OR 6.0 (95% CI 2.1–17.1)) than HIV-1 infected women (OR 2.2
(95% CI 1.0–4.8)) [59]. A previous survey conducted in Co ˆte
d’Ivoire by Laruche et al found that the prevalence of HIV-2
infection was higher in women suffering from ICC (13%)
compared to the referent group without any cervical lesion
(2.2%) (P=0.05). Inversely, the prevalence of HIV-1 in the
referent group (17%) did not differ from the HIV-1 prevalence in
women suffering from ICC (13%) (P=0.47) [56]. An association
between HIV-2 and squamous intra-epithelial lesions was also
found among Senegalese commercial sex workers by Langley et al
with an OR of 2.9 (95% CI 1.2–7.2) [58]. The pattern of HPV
genotypes among HPV-infected women has also been investigated
in Africa. A cross-sectional study determined the prevalence of
HPV infection, HIV infection, and cervical cytological abnormal-
ities in Ugandan women presenting to a sexually transmitted
infection clinic [60]. The authors reported 49 cases of HPV
infection among 106 women with cervical swabs adequate for
HPV testing (46.2%). Twenty-two cases of HPV infection were
identified in the 37 women found to be infected with HIV (59.5%)
and 27 in the 69 women not infected with HIV (39.1%). The most
commonly detected genotypes of HPV were 52 (14.2%), 16
(7.5%), 58 (7.5%) and 6 (6.6%), the 52, 16 and 58 types being
high-cancer risk genotypes and the 6 type being a low risk
genotype. Similarly, a study realized in Zambia among 145 HIV
infected women of which 93.8% had abnormal Pap smears, found
that high-risk genotypes, HPV 52 (37.2%), 58 (24.1%), and 53
(20.7%) were more frequent than HPV 16 (17.2%) and 18 (13.1%)
in women with high grade CIN or squamous cell carcinoma [61].
Non AIDS-defining cancers
Squamous cell carcinoma of the conjunctiva. Squamous
Cell Carcinoma of the Conjunctiva (SCCC) is a very rare tumor,
especially in Western countries where its incidence has been
estimated at 0.03 cases per 100 000 py [62]. In the USA, using
data from the HIV/AIDS Cancer Match Study, Frisch et al found
a significant association between this tumor of the conjunctiva and
HIV with a RR of 14.6 (95% CI 5.8–30.0) [44]. In a recent
publication, using data from the same registry study, Guech-
Onguey et al confirmed this association (SIR 12.2 (95% CI 6.8–
20.2)) in HIV-infected people [63].
Sub-Saharan Africa. SCCC has been recognized to be
associated with HIV in South Africa, Rwanda, Malawi and
Uganda since the early 90’s, with ORs ranging from 2.6 (95% CI
1.4–4.9) to 13.1 (95% CI 4.7–37.6) [23,64,65,66]. The other
known risk factors for this ocular tumor are intense exposure to
solar ultraviolet (UV) radiation and HPV infection [15]. The
influence of UV radiation has been established on several
occasions. We can cite as example the study published by
Newton et al in Uganda (2002). In this case-referent study, the
risk of SCCC increased with time spent cultivating corresponding
to direct sunlight exposure (Ptrend=0.05) [67]. Nevertheless the
interaction between UV exposure, HPV infection and HIV in the
genesis of SCCC is yet to be fully understood.
Hodgkin lymphoma. The incidence of HL is clearly
increased among HIV-infected patients [68]. Unusual clinical
and pathologic characteristics of HL have been described in this
setting such as systemic ‘‘B’’ symptoms i.e. fever, weight loss or
sweats are almost always present. Mixed cellularity and
lymphocyte depleted form of classical HL are the predominant
pathologic subtypes and bone marrow involvement is found in
about half of patients. Previous studies conducted in Western
countries showed that HL incidence was 7.8-fold (95% CI 4.4–13)
to 11.5-fold (95% CI 8.9–14.6) higher in persons with HIV/AIDS
[69,70,71] than in the general population. With the use of
HAART, the prognosis of HL has improved. In a retrospective
cohort study conducted in Germany, Hentrich et al found that
HIV patients without HAART had a 5.6-fold higher risk (95% CI
2.2–14.3) for 3-year mortality compared to patients under
HAART [72]. Another retrospective cohort study conducted in
France with a 15-year follow-up found an increase between the 2-
year survival rate in 1987–1996 at 45% (95%CI 32.3–57.8) and
the 2-year survival rate in 1997–2001 at 62% (95%CI 46.7–77.1)
[73]. However, HL incidence in persons with HIV/AIDS had
significantly increased since HAART introduction according to
the US nationwide study linkage conducted from 1980 to 2002
[69]. This study also displays a complex relation with the CD4
count, in which HL risk reaches a peak in moderately
immunosuppressed patients (i.e. 150–250. 10
6/L) and decreases
both in severely immunosuppressed subjects and in patients with a
rather normal CD4-cell count.
Sub-Saharan Africa. The record-linkage study conducted in
Uganda showed an association between HL and HIV/AIDS in
Africa with a SIR of 5.7 (95% CI 1.2–17) [21]. In Uganda,
Newton et al found that two of the four adults with HL (50%) were
HIV-seropositive compared to the 24 HIV-seropositive (21%)
from the control group (112 patients with cancer not known to be
related to an infectious aetiology) [23]. Case-referent studies from
South Africa also found an excess of risk of HL among HIV-
infected patients with ORs of 1.4 (95% CI 0.7–2.8) and 1.6 (95%
CI 1.0–2.7) [18,20].
Lung cancer. HIV-infected persons have an elevated risk for
lung cancer, varying from two to seven-fold higher than the
general population according to several cohort studies
[74,75,76,77,78]. In 2007, using data from the HIV/AIDS
Cancer Match Study, Chaturverdi et al confirmed this
association with an overall SIR of 3.8 (95% CI 3.6–4.1). This
study also highlighted that this association was especially strong
among young HIV-infected people aged 15 to 29 years with a SIR
of 10.4 (95% CI 3.8–22.7) [79]. A cohort study of intravenous
drug abusers conducted by Kirk et al has shown the independent
role of HIV infection in lung cancer. Indeed, smoking which is the
HIV and Cancer in Africa
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people with HIV/AIDS and partly explains the increased
incidence of lung cancer in this population. After age, sex,
smoking status and calendar period adjustment, the relative risk of
developing lung cancer was 3.6 (95% CI 1.6–7.9) in HIV-infected
versus HIV-negative people [80].
Sub-Saharan Africa. The record linkage study conducted in
Kampala, Uganda, showed a higher incidence of lung cancer in
HIV-infected people with a SIR of 5.0 (95% CI 1.0–15.0) [21]. By
contrast in a previous case-referent study, Sitas et al did not find
any association between lung cancer and HIV with an OR of 1.0
(95% CI 0.5–2.3) [18].
Hepatocellular carcinoma. The most common risk factors
for hepatocellular carcinoma (HCC) are hepatitis B or C virus
(HBV, HCV) infection, chronic alcohol intake as well as
aflatoxines in the diet in Africa. Although the etiological link
between HCC and HBV and HCV is well documented, the
influence of HIV infection and immune status on the development
of this type of liver cancer is unclear and particularly pertinent for
Africa [81]. In the Swiss HIV Cohort study, Clifford et al. found a
higher rate of liver cancer among HIV-infected people with a SIR
of 7 (95% CI 2.2–16.5) [75], similar to an eight-fold risk identified
in people with AIDS in the USA [82]. The excess of liver cancer
was less clear among HIV-infected people in an early study [83].
This association between HIV and liver cancer found in Western
countries may be partly explained by co-infection with HBV and/
or HCV among intravenous drug users. Thus, it is difficult to
assess the specific role of HIV in the carcinogenesis of liver cancer.
Nevertheless, previous publications showed that co-infection with
HIV and HCV or HBV led to a higher mortality from liver cancer
than HCV or HBV alone [84,85]. The French GERMIVIC Joint
Study Group Network reported an increase in the prevalence of
HCC as a cause of death among HIV-infected persons between
1995 and 2001 (respectively 4.7% and 25% of all deaths) [86].
Sub-Saharan Africa. In some parts of Africa, especially in
West Africa where HBV infection is endemic, liver cancer is highly
prevalent. In a publication from the Gambia Liver Cancer Study,
HCC was the commonest cancer and 15% to 20% of the total
population are chronic HBV carriers [87]. Few studies have
evaluated the association between liver cancer and HIV in sub-
Saharan Africa. According to the case-referent study conducted by
Newton et al in Uganda, with a referent group of cancers not related
to an infectious etiology, being HIV-infected was only associated with
a slight risk of HCC (OR 1.2 (95% CI 0.3–4.2)) [23].
Breast cancer. Early studies on breast cancer showed that
the incidence was lower in HIV-infected than HIV-negative
women [82,83]. Indeed, in a recent publication from the US
HIV/AIDS Cancer Match Registry Study Group, Goedert et al
found that local stage breast cancer risk among HIV-infected
women increased when comparing the 1990–1995 and 1996–2002
cohorts from a SIR=0.40 (0.22–0.66) to a SIR=0.61 (0.38–0.93),
yet still remaining lower than the risk of the general population.
Similarly, the SIRs for regional stage breast cancer went from 0.53
(0.29–0.88) to 0.77 (0.47–1.19) [88].
Sub-Saharan Africa. The reduced breast cancer incidence in
HIV-infected patients initially described in Western countries has
also been found in Africa. Data collected between 1968 and 1996
by the Tanzanian cancer registry showed a significant reduction in
the incidence of breast cancer in women as well as men with HIV
[89]. One year later, another study emphasized that women below
50 years of age with breast cancer were much less likely to be HIV-
infected with an OR of 0.18 (95% CI 0.04–0.76) [90].
Other cancers. Anal cancer is closely associated with HIV
infection. Bower et al showed that the anal cancer incidence rate of
60 cases per 100 000 py was 120-fold higher in HIV-infected
persons than in the general population (0.5 cases per 100 000 py)
[91]. In another study, the SIR of anal cancer were respectively of
18.3 (95% CI 9.1–32.7) and 19.6 (95% CI 14.2–26.4) in 1980–
1989 and 1990–2002 respectively. In the same study, the incidence
of penile cancer was higher among HIV-infected men with SIRs of
5.6 (95% CI 1.8–13.1) and 2.2 (95% CI 2.2–20.6) for the same
study periods [76].
Sub-Saharan Africa. Some HPV-related malignancies such
as anogenital cancers (other than cervical cancer) have also be
shown to be related to HIV infection with ORs of 4.8 (95% CI
1.9–12.2) and 2.2 (95% CI 1.4–3.3) in the case-referent studies
conducted in South Africa [18,20]. In Uganda, Newton et al found
an increased risk of penile cancer in HIV-infected men with an
OR of 13.0 (95% CI 1.4–122) [23]. Concurrently, the record
linkage study from Kampala, Uganda found several cancer sites to
be associated with a higher occurrence in HIV-infected
populations such as kidney, thyroid and uterus with respective
SIRs of 16 (95% CI 1.8–58), 5.7 (95% CI 1.1–16) and 5.5 (95% CI
1.5–14) [21].
Recent findings from a case-referent study conducted by Stein
et al found that skin squamous cell carcinoma was associated with
HIV infection (OR 2.6 (95% CI 1.4–4.9)) [20]. This finding is
consistent with other studies from Western countries in HIV-
infected patients which found even more increased risks of non
melanoma skin cancer with unusual locations [83,92,93].
Discussion
AIDS-defining cancers
Publications that aimed to assess the association between AIDS-
defining cancers and HIV/AIDS in sub-Saharan Africa showed
that KS and NHL, known to be directly linked to the severity of
immunosupression, were strongly and significantly associated with
HIV/AIDS. This association was much weaker for ICC.
For KS, the reduced association observed among African HIV-
infected populations compared to the one of industrialized
countries might be related to the high background risk of KS
among HIV-negative individuals in Africa and the higher
seroprevalence of HHV8 reported in sub-Saharan Africa or the
influence of other co-factors [94,95]. The persistence of a high
incidence of KS in Africa is in contradiction with its decrease in
Western countries, possibly related to the limited use of expensive
antiretroviral therapies. Indeed the scale-up of HAART in sub-
Saharan countries may be the best way for controlling the disease,
immune restoration being the basis of the KS care. However, a
small subset of HIV-infected patients with a low CD4+ T-cell
count at the initiation of HAART, may develop HIV-KS immune
reconstitution inflammatory syndrome (IRIS) within weeks
thereafter [96].
A weaker association was found between HIV and NHL in sub-
Saharan Africa compared to industrialized countries. This result
might be partly explained by the under-ascertainment of NHL in
middle and low-income settings, particularly marked for HIV
positive subjects. Indeed, from a clinical point of view, as this
malignancy requires a costly histological diagnosis it is possible
that many patients presenting with polyadenopathies might have
been classified as tuberculosis and died without any histological
exploration. In addition, NHL cerebral localization has to be
differentiated from current infectious opportunistic conditions
such as cryptoccocosis (which is quite easy to diagnose), cerebral
toxoplasmosis or cytomegalovirus (CMV) infection which remain
challenging diagnoses in countries with limited facilities. In this
respect, Lucas et al conducted a study on a necropsic series of HIV-
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histological NHL [97]. A lower susceptibility to NHL among
African HIV+ populations has also been hypothesized since in the
USA, between 1981 and 1994, the proportion of NHL as an
AIDS-defining illness was estimated lower in the black (1%)
compared to the white population (3%) [98], although no specific
genetic argument definitively supports this hypothesis.
Although there appears to be a clear association between HIV
infection and the occurrence of CIN, ICC has been somewhat less
strongly associated with HIV in sub-Saharan Africa than in
Western countries. Like NHL, this lower association could be due
to the competing risk of mortality from other conditions associated
with HIV, particularly in settings where HAART is not widely
available [52]. A high background risk of ICC among African
women may have, to some extent, blurred the impact of HIV on
the OR estimates in case-referent studies [99]. The tighter
association found between HIV-2 and cervical abnormalities
compared to HIV-1 supports the hypothesis that African HIV-1
infected women might die of an opportunistic infection before
developing high-grade CIN or ICC, as HIV-2 is known to be less
aggressive and having a longer incubation period than HIV-1.
Results from several studies conducted in African countries
[60,61,100,101] showed that the patterns of HPV genotypes
found are quite different from the ones observed in Europe and
United States where HPV 16 and 18 (among the high-risk
genotypes) predominate in the latter [40]. These findings may
have relevant population health implications in sub-Saharan
Africa as today most existing HPV vaccines contain only the 16
and 18 carcinogenic genotypes. Therefore, the potential role of
HPV vaccination strategies on the African continent still needs to
be determined. ICC is the commonest malignancy in women in
several African countries, independently from their HIV status.
Most women with cervical cancer are presenting with a late-stage
disease [102]. These arguments highlight that defining the impact
of HIV infection on CIN and ICC has important implications for
HIV-infected patients and for population health programs in sub-
Saharan Africa since effective and low cost screening tools for
cervical screening such as visual inspection of the cervix are
already available and need to be implemented [103].
Non-AIDS defining cancers
The association between HIV infection and HL in Uganda was
consistent with previous findings from other studies conducted in
Western countries. Inversely, the association between SCCC and
HIV infection was primarily and more frequently documented in
sub-Saharan Africa rather than Western countries. Even if this
difference is partly explained by the higher exposure to solar UV
radiations, a well known risk factor of SCCC, the impact of HIV
infection on the occurrence of malignancies found in Southern
countries may not be directly extrapolated from the Western one.
Indeed, confounding factors such as local climatic conditions and
particular innate immunity should be sought. Certain non AIDS-
defining cancers like skin cancers are also thought to occur with
increased frequency or altered course in patients with HIV. This is
the case of squamous carcinoma of the skin which shares close
patterns with SCCC [83,92,93].
There is a real need to describe the patterns of malignancies in
African populations as they may not share the same genetic
background and as they are not exposed to the same degree to
some carcinogenic factors such as solar UV radiation, endemic
HBV and EBV infections as well as food contaminations by
aflatoxins among others [104]. Recent findings from India by Dhir
et al emphasized the specificity of the spectrum of HIV/AIDS
related cancers in Southern countries. This study conducted in the
largest referral cancer centre of Mumbai, India during a four-year
period found no case of KS in patients with HIV/AIDS [105]. An
important issue in the occurrence of malignancies in HIV-positive
individuals is the level of immunodepression as well as its duration.
Given the limited availability of HAART in Africa so far, a higher
risk of occurrence of KS and to a lesser degree NHL is expected
among HIV-positive Africans than HIV-positive in the rest of the
world despite the fact that RR of these diseases are lower in the
South than in the North. This could also explain the weaker
association between HIV and HL. By contrast the role of more
frequent co-infections leading to chronic inflammation may be
associated with a different tumor profile.
Women now constitute almost half of all AIDS cases. With the
increasing use of HAART in sub-Saharan Africa, the overall
health and survival of HIV individuals is expected to improve in
the coming years. Based on epidemiologic data from Western
countries and Africa, HIV infection is not considered as permissive
for breast cancer [106]. This may partly reflect the paucity of
available data. In addition, breast cancer diagnosis is usually done
in women in the second half of their life whereas HIV-infected
women are considered until now to have limited life expectancy
[90]. Furthermore, screening accessibility in resource-limited
countries is still lacking for this condition. Thus, as the HIV
population is going to mature, it can be expected that breast
cancer in seropositive women will be more often diagnosed.
Results from non AIDS-defining cancers available from the few
studies that were conducted so far are based on small-sized
populations. This lack of power partly explains the wide
confidence intervals associated with estimated SIRs and ORs in
these studies. As a number of non AIDS-defining cancers occur
with a relatively low incidence, available studies are limited to
evaluate the association between cancer and HIV. There is a need
for wide and prospective data collection in order to monitor cancer
events among HIV-infected persons in low-income settings.
The incidence rate ratio is the most appropriate statistic for
making comparisons between populations for which incidence
rates are computed. For that purpose the main method to
quantify cancer occurrence in an HIV-infected cohort relies on
linkage studies between cancer registries and HIV/AIDS
databases. Such studies are actually conducted in Western
countries [76,107], where they can rely on population-based
cancer registries. Unfortunately, there is a paucity of such
cancer registries on the African continent [108]. In this regard,
the linkage study conducted in Uganda between the Kampala
cancer registry and the AIDS support organization database
provided a valuable tool for future investigations because it
clearly demonstrates the feasibility of such an approach [21].
Another way to assess cancer occurrence in HIV-infected
cohorts is to set up a systematic reporting and registering of
cancer on their data collection forms. The International
epidemiological Database to Evaluate AIDS (IeDEA) initiative
(http://www.iedea-hiv.org) offers an interesting opportunity to
set up a standardized case reporting system of malignancies in
every region of the world involved in this collaboration (four on
the African continent) that will allow valid comparisons
between HIV-infected cohorts. By collecting and harmonizing
data from many HIV/AIDS cohorts from Western and
Southern countries, this initiative will address unique and
evolving research questions in HIV/AIDS such as its associa-
tion with malignancies currently unanswerable by single
cohorts.
So far, the epidemiological studies have focused on the strength
and precision of the associations between the different malignan-
cies and HIV infection. Not only the new studies will have to
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controversial findings for specific tumors, they will also need to
estimate for the first time the general population attributable
risk and more importantly perhaps the attributable risk in the
exposed (HIV-infected) population that will may deserve focused
interventions.
Conclusion
In Western countries, as HAART has improved the survival of
HIV/AIDS patients, the cumulative risk of developing, and dying
from, non AIDS-defining cancers is likely to increase. In sub-
Saharan Africa, morbidity and mortality are mainly caused by
transmissible diseases and complications of HIV-infection are
predominantly of infectious origin. With the worldwide scale-up of
HAART, chronic conditions such as cancer are likely to represent
a growing part in the burden of the HIV-associated morbidity.
Some studies in sub-Saharan Africa show that HIV infection is
already associated with AIDS-classifying cancers and others
provide some evidence of an association between HIV and non-
AIDS classifying neoplasia. African researchers need to implement
now large and well-designed population-based studies in order to
better define the spectrum of HIV-associated malignancies and the
most effective strategies for their prevention, screening and
treatment.
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